Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
4.13 +0.05 (+1.23%) 04/11/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 4.13 unch (unch) 16:02 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
3.95
Day High
4.16
Open 4.16
Previous Close 4.08 4.08
Volume 542,200 542,200
Avg Vol 718,715 718,715
Stochastic %K 25.07% 25.07%
Weighted Alpha -13.11 -13.11
5-Day Change -0.01 (-0.24%) -0.01 (-0.24%)
52-Week Range 3.85 - 6.75 3.85 - 6.75
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 240,845
  • Shares Outstanding, K 58,316
  • Annual Sales, $ 198,770 K
  • Annual Income, $ -18,900 K
  • EBIT $ -33 M
  • EBITDA $ -32 M
  • 60-Month Beta 0.72
  • Price/Sales 1.20
  • Price/Cash Flow N/A
  • Price/Book 0.44

Options Overview Details

View History
  • Implied Volatility 85.29% ( -46.44%)
  • Historical Volatility 40.11%
  • IV Percentile 84%
  • IV Rank 36.55%
  • IV High 201.21% on 01/22/25
  • IV Low 18.50% on 09/26/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 272
  • Volume Avg (30-Day) 355
  • Put/Call OI Ratio 1.89
  • Today's Open Interest 12,552
  • Open Int (30-Day) 9,454

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.55
  • Number of Estimates 2
  • High Estimate -0.52
  • Low Estimate -0.58
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -685.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.85 +7.27%
on 04/09/25
Period Open: 4.98
5.16 -19.88%
on 03/17/25
-0.85 (-17.07%)
since 03/11/25
3-Month
3.85 +7.27%
on 04/09/25
Period Open: 4.60
5.19 -20.42%
on 03/06/25
-0.47 (-10.22%)
since 01/10/25
52-Week
3.85 +7.27%
on 04/09/25
Period Open: 4.28
6.75 -38.81%
on 06/13/24
-0.15 (-3.50%)
since 04/11/24

Most Recent Stories

More News
Vanda: Q4 Earnings Snapshot

Vanda: Q4 Earnings Snapshot

VNDA : 4.13 (+1.23%)
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

Shares of Kodiak Sciences KOD have skyrocketed 270.7% in the past six months fueled by updates from the developmental program of its lead investigational candidate, tarcocimab. It is a novel anti-VEGF...

KOD : 2.18 (+4.06%)
CTMX : 0.5325 (+7.66%)
CSTL : 19.70 (+2.07%)
VNDA : 4.13 (+1.23%)
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

The year 2024 has been a mixed ride for the biotech industry. It started on a positive note, attracting investors’ attention in areas with great commercial potential, like obesity, immunology and gene...

ALLO : 1.4500 (+5.84%)
RZLT : 2.47 (unch)
VNDA : 4.13 (+1.23%)
New Strong Buy Stocks for November 14th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Vanda Pharmaceuticals Inc. VNDA: This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings...

TSQ : 6.97 (+0.43%)
SPPJY : 1.9000 (-1.04%)
VMEO : 4.81 (-1.43%)
TBI : 4.17 (-5.01%)
VNDA : 4.13 (+1.23%)
Vanda: Q3 Earnings Snapshot

Vanda: Q3 Earnings Snapshot

VNDA : 4.13 (+1.23%)
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More

Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.Here's...

JAZZ : 100.50 (-1.52%)
EXEL : 35.31 (+2.47%)
NVAX : 5.86 (+7.92%)
VNDA : 4.13 (+1.23%)
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today

A regulator's decision drained the market's enthusiasm for the company.

VNDA : 4.13 (+1.23%)
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment

New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves targeted...

ALZN : 0.7672 (-0.36%)
VNDA : 4.13 (+1.23%)
ITCI : 131.87 (-0.04%)
TEVA : 13.46 (+4.99%)
ABBV : 175.05 (+0.49%)
Vanda: Q2 Earnings Snapshot

Vanda: Q2 Earnings Snapshot

VNDA : 4.13 (+1.23%)
Accenture, KB Home rise; Snap, Jabil fall, Thursday, 6/20/2024

Stocks that traded heavily or had substantial price changes on Thursday: Accenture, KB Home rise; Snap, Jabil fall

CG : 36.23 (-1.09%)
CMC : 41.89 (+0.10%)
VNDA : 4.13 (+1.23%)
DFS : 157.04 (-1.00%)
SNAP : 7.96 (+1.66%)
KBH : 50.90 (-0.97%)
ACN : 284.34 (-0.31%)
Vanda: Q1 Earnings Snapshot

Vanda: Q1 Earnings Snapshot

VNDA : 4.13 (+1.23%)
Why Vanda Pharmaceuticals Stock Is Skyrocketing Today

Future Pak wants Vanda, but Vanda doesn't want Future Pak.

VNDA : 4.13 (+1.23%)
Vanda: Q4 Earnings Snapshot

Vanda: Q4 Earnings Snapshot

VNDA : 4.13 (+1.23%)
Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation

/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced its intention to file a petition for a writ of certiorari in its HETLIOZ®...

VNDA : 4.13 (+1.23%)
Vanda Pharmaceuticals Announces Participation in the Jefferies Inaugural Biotech CNS/Neuro Summit

/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies Inaugural Biotech...

VNDA : 4.13 (+1.23%)
Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference

/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the H.C. Wainwright Global Investment...

VNDA : 4.13 (+1.23%)
Why Shares of Vanda Pharmaceuticals Are Dropping on Tuesday

The pharmaceutical company's stock hit another 52-week low.

VNDA : 4.13 (+1.23%)
Vanda: Q2 Earnings Snapshot

Vanda: Q2 Earnings Snapshot

VNDA : 4.13 (+1.23%)
Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2023....

VNDA : 4.13 (+1.23%)
Vanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023

/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2023 on Thursday, July 27,...

VNDA : 4.13 (+1.23%)

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Key Turning Points

3rd Resistance Point 4.42
2nd Resistance Point 4.29
1st Resistance Point 4.21
Last Price 4.13
1st Support Level 4.00
2nd Support Level 3.87
3rd Support Level 3.79

See More

52-Week High 6.75
Fibonacci 61.8% 5.64
Fibonacci 50% 5.30
Fibonacci 38.2% 4.96
Last Price 4.13
52-Week Low 3.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar